Monthly Formulary Amendments – June 2023
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in June 2023.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Budget impact of methylphenidate modified release tablet choice
The purpose of this bulletin is to highlight the difference in cost between bioequivalent methylphenidate modified release (MR) tablets. It considers the budget impact of MR tablet choice and shows the yearly primary care spend on all methylphenidate XL tablets, and the proportion of this spend on each of the available brands.
Monthly Horizon Scanning Report – June 2023
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Monthly Financial Headlines
Overview
This report monitors budget performance based on total prescribing for the whole BNF at ICB, sub-ICB and PCN level for the financial year to date with particular focus on cost and item growth compared to the same period from the previous financial year.
Frequency
Monthly
Data period
June 2023
Top 50 BNF sections and drugs
Overview
This report looks at the top 50 BNF sections and drugs in terms of spend at ICB and SICBL level for the financial year to date with a focus on cost growth and item growth.
Frequency
Quarterly
Data period
April 2023 to June 2023
Monthly Formulary Amendments – June 2022
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in June 2022.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Budesonide orodispersible tablets for maintenance of remission in eosinophilic oesophagitis
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
Budesonide orodispersible tablets (Jorveza) are indicated for induction and maintenance of remission in adults with eosinophilic oesophagitis. A NICE technology appraisal recommended budesonide ODT for induction of remission but did not address maintenance. This review assesses the evidence for use in maintenance treatment.
Download the full review below to read more.
Electronic repeat dispensing: Understanding the prescribing population & initial barriers to uptake
Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.
This report highlights the benefits of electronic repeat dispensing (eRD) and examines its use at ICS level in the North of England, in order to support systems in identifying where prescribing processes may be further streamlined.
Monthly Horizon Scanning Report – June 2022
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Items not to be routinely prescribed
Overview
This report looks at prescribing trends for items which should not be routinely prescribed in primary care at CCG and STP level based on the NHS England national consultation in July – October 2017. The report monitors the prescribing spend trends for the final list of 26 items.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2021 to June 2021
This report has been discontinued. If you would like an updated version of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net